Literature DB >> 412588

Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys.

S M El Dareer, V M White, F P Chen, L B Mellet, D L Hill.   

Abstract

An extraction procedure that allows measurement of [3H]vincristine and its metabolites in biologic fluids and tissues has been developed and used to determine the distribution and metabolism of vincristine in mice, rats, dogs, and monkeys. Very little tritium exchange occurred during the experiments. In mice and rats injected ip with [3H]vincristine, the peak serum levels of drug were reached at 15 minutes. For both mice and rats, the concentration of vincristine metabolites rose in the serum for 30 minutes, then remained high through 3 hours. For dogs and monkeys given an iv dose of [3H]vincristine, the initial serum levels fell rapidly, with half-lives for the first phase of 6 and 10 minutes respectively. The half-life for both of the second phases was 190 minutes. For both species, the serum level of metabolites fell for 2 hours, then remained relatively constant. These results were not appreciably altered when the animals were injected simultaneously with prednisone. Compared to serum levels in mice, rats, dogs, and monkeys, there was a marked accumulation of [3H]vincristine in all tissues examined, except the brain. The pancreas, spleen, kidneys, lungs, and liver of dogs and monkeys contained the largest amounts. The tissue distribution was not greatly different in dogs and monkeys injected simultaneously with prednisone. Urinary excretion of intact vincristine and its metabolites was observed for all four species. Both vincristine and its metabolites appeared in the bile of dogs and monkeys.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 412588

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  14 in total

1.  Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers.

Authors:  Helen H Usansky; Patrick J Sinko
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

2.  Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors.

Authors:  Fan Wang; Feng Zhou; Gary D Kruh; James M Gallo
Journal:  Neuro Oncol       Date:  2010-05-25       Impact factor: 12.300

3.  Vincristine infusion. A phase I study.

Authors:  W Weber; G A Nagel; E Nagel-Studer; R Albrecht
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  A sensitive radioimmunoassay for vincristine and vinblastine.

Authors:  V S Sethi; S S Burton; D V Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 5.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

Authors:  O van Tellingen; J H Beijnen; W J Nooijen; A Bult
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.

Authors:  V S Sethi; P Surratt; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

Authors:  O van Tellingen; A V Kuijpers; J H Beijnen; W J Nooijen; A Bult
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

10.  The stathmokinetic (mitostatic) effect of vincristine and vinblastine on human gliomas.

Authors:  T Hoshino; C B Wilson; I Muraoka
Journal:  Acta Neuropathol       Date:  1979-06-15       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.